Australia's largest stock trading and investment forum Australia's #1 stock forum

IMU

0.00%

4.8¢ imugene limited

Ann: First patient dosed in Phase 1 bile tract cancer trial, page-118

First 118 Last

Share
Profile

Follow
Ianwil

13,346 Posts.

953

09/08/24

10:47

Post #: 75138390
Share

Originally posted by CastawayGS ↑

Having been a holder for a while and continue to increase my exposure to this stock (while certainly being no expert on immunotherapy) I would say that this is the trial I am most excited about. Unlike the previous trial whose data update jumped the price last year, this trial has many more attributes...

Firstly, it is with higher dosage levels, which must be starting to get close to OBD???

Secondly, I believe it is not with patients that have had other lines of treatment and hence don't have a greatly reduced immune system. Which is really import when trying to establish the effectiveness of an immunotherapy drug.

And thirdly, I think it has been even more sanctioned, and hence watched, by the FDA as this particular cancer has no existing effective treatment.

I understand that bile duct cancer is a limited market, so IMU will not go on to riches just for this particular line of treatment. But of course, when it is proven to work for one type of cancer, then people are going to give it more attention and consider it for others.

So, if the study in mice is ultimately replicated in humans, then hold on to your hat. Actually, it is more of a case of pull up a chair, read the paper and have a nice bottle of wine over a very long period. This is not a rocket, it is instead a great test of patience and perseverance. But ohhhhh, what a goal.

Expand

Not a Murdoch paper, you might get the wrong advise.

IMU Price at posting: 5.4¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 16 more messages in this thread...

First 118 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.000(0.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
4.9¢	4.9¢	4.8¢	$328.5K	6.792M

Buyers (Bids)

No.	Vol.	Price($)
45	5443565	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	2171910	5

View Market Depth

No.	Vol.	Price($)
45	5443565	0.048
43	4562182	0.047
49	3188200	0.046
61	6392230	0.045
12	2001364	0.044

Price($)	Vol.	No.
0.049	2171910	5
0.050	4756889	17
0.051	6179811	13
0.052	2579418	10
0.053	1158504	8

Last trade - 16.10pm 04/10/2024 (20 minute delay)

IMU (ASX) Chart

Ann: First patient dosed in Phase 1 bile tract cancer trial, page-118

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: First patient dosed in Phase 1 bile tract cancer trial, page-118

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News